Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine

Gene Therapy

Volumn 6, Issue 8, 1999, Pages 1475-1481

  Kayaga, J ^a   Souberbielle, B E ^b,c   Sheikh, N ^d   Morrow, W J W ^d   Scott Taylor, T ^a   Vile, R ^e   Dalgleish, A G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Allogeneic vaccination; B16 F10 melanoma; GM CSF

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; GENETICS; HUMAN; HUMAN CELL; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; VACCINATION;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSDUCTION, GENETIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032822960     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300961     Document Type: Article

References (40)

1. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
2. Vieweg J et al. Immunotherapy of prostate cancer in the dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res 1994; 54: 1760-1765.
3. Dunussi-Joannopoulos K et al. Gene immunotherapy in murine acute myeloid more potent antitumour immunity compared with B7 family and other cytokine vaccines. Blood 1998; 91: 222-230.
4. Simons JW et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
5. Huang AY et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 1994; 264: 961-965.
6. Maass G et al. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci USA 1995; 92: 5540-5544.
7. Schweighoffer T, Schmidt W, Buschle M, Birnstiel ML. Depletion of naive T cells of the peripheral lymph nodes abrogates systemic antitumour protection conferred by IL-2 secreting cancer vaccines. Gene Therapy 1996; 3: 819-824.
8. Souberbielle BE et al. Comparison of four strategies for tumour vaccination in the B16-F10 melanoma model. Gene Therapy 1998; 5: 1447-1454.
9. Robbins PF, El-Gamil M, Kawakami Y, Rosenberg SA. Recognition of immunotherapy. Cancer Res 1994; 54: 3124-3126.
10. Brichard V et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 1993; 178: 489-195.
11. Van Der Bruggen P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
12. Dalgleish A. The case for therapeutic vaccines. Melanoma Res 1996; 6: 5-10.
13. Ashley DM et al. A genetically modified allogeneic cellular vaccine generates MHC class I-restricted responses against tumor associated antigens and protects against CNS tumors in vivo. J Neuroimmunol 1997; 78: 34-46.
14. Kim TS, Russell SJ, Collins MK, Cohen EP. Immunity to B16 melanoma in mice immunized with IL-2 secreting allogeneic mouse fibroblasts expressing melanoma associated antigens. Int J Cancer 1992; 51: 283-289.
15. Kim TS, Russell SJ, Collins MK, Cohen EP. Immunization with interleukin-2-secreting allogeneic mouse fibroblasts expressing melanoma associated antigens prolongs the survival of mice with melanoma. Int J Cancer 1993; 55: 865-872.
16. Toes RE et al. Protective antitumour immunity induced by immunization with completely allogeneic tumour cells. Cancer Res 1996; 56: 3782-3787.
17. Kim YS, Slomski R, Cohen EP. Immunity to melanoma in mice immunized with transfected mouse fibroblasts expressing melanoma associated antigens. Cancer Immunol Immunother 1991; 34: 163-168.
18. Knight BC et al. Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 1996; 6: 299-306.
19. Morton DL et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 465-470.
20. Arienti F et al. Limited antitumour T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1996; 7: 1955-1963.
21. Bowman LC et al. Interleukin-2 gene modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther 1993; 9: 835-843.
22. Thomas MC, Greten TF, Pardoll DM, Jaffee EM. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine. Hum Gene Ther 1998; 9: 835-843.
23. Jaffee EM et al. A phase I clinical trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Hum Gene Ther 1998; 9: 1951-1971.
24. Inaba K et al. Identification of proliferating dendritic cell precursors in mouse blood. J Exp Med 1992; 175: 1157-1167.
25. Bevan MJ. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 1995; 182: 639-641.
26. Hearing VJ. Murine melanoma-specific tumour rejection activity elicited by a purified, melanoma associated antigen. J Immunol 1986; 137: 379-384.
27. Bernhard H et al. Cellular immune responses to human renal cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T lymphocytes (CTL) clones. Int J Cancer 1994; 59: 807-842.
28. Weynants P. Expression of mage genes by non-small-cell lung carcinomas. Int J Cancer 1994; 56; 826-829.
29. Aruga A, Aruga E, Chang AE. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumour vaccine adjuvant. Cancer Res 1997; 57: 3230-3237.
30. Castleden SA et al. A family of bicistronic vectors to enhance both local and systemic antitumour effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther 1997; 8: 2087-2102.
31. Yu JS, Burwick JA, Dranoff G, Breakefield XO. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor transduced tumor cells. Hum Gene Ther 1997; 8: 1065-1072.
32. Parney IF et al. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogeneic Hu-PBL-SCID/Beige mouse-human glioblastoma multiforme model. Hum Gene Ther 1997; 8: 1073-1085.
33. Hrouda D et al. Allogeneic whole tumour cell vaccination in the rat model of prostate cancer. Cancer Res (submitted).
34. Ben-Yosef R, Or R, Nagler A, Slavin S. Graft-versus-tumour and graft-versus-leukaemia effect in a patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet 1996; 348: 1242-1243.
35. Eibl B et al. Evidence for a graft-versus-tumour effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501-1508.
36. Fidler IJ. Biological behavior of malignant tumor cells correlated to their survival in vivo. Cancer Res 1975; 35: 218-224.
37. Kripke ML. Speculations on the role of ultraviolet radiation in the development of malignant melanoma. J Natl Cancer Inst 1979; 63: 541-545.
38. Sugiura K, Stock CC. Studies in a tumour spectrum III: the effect of phosphoramides on the growth of a variety of mouse and rat tumours. Cancer Res 1955; 15: 38-51.
39. Cobbold SP et al. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 1984; 312: 548-551.
40. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection and complimentary helper-free packaging cell line. Nucleic Acids Res 1990; 18: 3587-3596.